Mabvax Therapeutics Holdings Inc

Find more results for NASDAQ:TELK

Officers and directors

J. David Hansen
Chairman of the Board, President, Chief Executive Officer
Gregory P. Hanson
Chief Financial Officer
Philip O. Livingston M.D.
Chief Science Officer, Director
Paul W. Maffuid Ph.D.
Vice President - Pharmaceutical Development and Operations
Paul Resnick M.D.
Vice President and Chief Business Officer
Wolfgang W. Scholz Ph.D.
Vice President - Antibody Discovery
Jeffrey F. Eisenberg
Kenneth M. Cohen
Independent Director
Robert E. Hoffman
Independent Director
Paul V. Maier
Independent Director


11535 Sorrento Valley Rd Ste 400
SAN DIEGO, CA 92121-1309
United States - Map
+1-858-2599405 (Phone)

Website links

MabVax Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of human monoclonal antibody products and vaccines for the diagnosis and treatment of various cancers. The Company has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients immunized against targeted cancers. The Company's lead antibody candidate, HuMab-5B1, is being developed as a therapeutic product and as a diagnostic imaging product. The antibody targets carbohydrate antigen sialyl Lewisa (sLea), which is expressed on tumors of the gastrointestinal tract, including pancreatic, colon and stomach cancers, as well as ovarian, breast and small cell lung cancers. The Company is also developing the HuMab-5B1 antibody conjugated to a radiolabel as a positron emission tomography (PET) imaging agent to assist in the diagnosis of pancreatic cancer.

Related companies